The effect of cilostazol on glucose tolerance and insulin resistance in a rat model of non-insulin dependent diabetes mellitus.
BACKGROUND
It has been reported that many peripheral vasodilating drugs might improve insulin resistance. Cilostazol, a antithrombotic agent, increases peripheral blood flow in non-insulin dependent diabetic patients. The effect of cilostazol treatment on insulin resistance in streptozotocin (STZ)-induced non-insulin dependent diabetic Wistar rats was examined.


METHODS
About a half of two-day old neonate siblings were injected intraperitoneally with STZ and maintained for six months, at which time they were compared with age-matched control rats for intraperitoneal glucose tolerance test (IPGTT) and for glucose infusion rate (GINF) in a euglycemic hyperinsulinemic glucose-clamp study. After that, these studies were also performed after feeding rat chow containing cilostazol (100 mg/kg/day) to rats with STZ-induced non-insulin dependent diabetes mellitus for four-weeks and compared with those of age-matched control rats.


RESULTS
In the intraperitoneal glucose tolerance test studies, plasma glucose levels of STZ-induced non-insulin dependent diabetic rats were significantly higher and plasma insulin levels significantly lower than those of age-matched control rats in the age of six months. Glucose infusion rate was lower in STZ-induced non-insulin dependent diabetic rats than those of age-matched control rats. However, after a four-week cilostazol treatment, glucose infusion rate of STZ-induced non-insulin dependent diabetic rats was not significantly different from that of control rats.


CONCLUSIONS
These findings suggested that cilostazol may improve insulin resistance in STZ-induced non-insulin dependent diabetic rats.
Chang
S A
SA
Department of Internal Medicine, Catholic University Medical College, Seoul, Korea.
Cha
B Y
BY
Yoo
S J
SJ
Ahn
Y B
YB
Song
K H
KH
Han
J H
JH
Lee
J M
JM
Son
H S
HS
Yoon
K H
KH
Kang
M I
MI
Lee
K W
KW
Son
H Y
HY
Kang
S K
SK
D000818:Animals; D000831:Animals, Newborn; D001786:Blood Glucose / Q000187:drug effects*; D000077407:Cilostazol; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced / Q000188:drug therapy*; D004195:Disease Models, Animal; D005951:Glucose Tolerance Test; D007333:Insulin Resistance; D008297:Male; D011336:Probability; D051381:Rats; D017208:Rats, Wistar; D012016:Reference Values; D012680:Sensitivity and Specificity; D013311:Streptozocin; D013777:Tetrazoles / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000494:pharmacology*
D001786:Blood Glucose; D013777:Tetrazoles; D014665:Vasodilator Agents; D013311:Streptozocin; D000077407:Cilostazol